ASP Isotopes (NASDAQ:ASPI) Director Michael Gorley Sells 30,000 Shares

ASP Isotopes Inc. (NASDAQ:ASPI) Director Michael Gorley sold 30,000 shares of the business’s stock in a transaction that occurred on Tuesday, June 30th. The shares were sold at an average price of $6.27, for a total value of $188,100.00. Following the completion of the sale, the director owned 87,908 shares of the company’s stock, valued at approximately $551,183.16. This represents a 25.44% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

ASP Isotopes Stock Performance

Shares of ASPI opened at $6.17 on Thursday. The company has a current ratio of 4.39, a quick ratio of 4.37 and a debt-to-equity ratio of 0.69. The firm has a market cap of $776.80 million, a PE ratio of -2.97 and a beta of 3.51. The company’s 50 day simple moving average is $6.24 and its 200-day simple moving average is $5.90. ASP Isotopes Inc. has a 12-month low of $3.92 and a 12-month high of $14.49.

ASP Isotopes (NASDAQ:ASPI) last released its quarterly earnings results on Wednesday, May 20th. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.28) by $0.06. ASP Isotopes had a negative net margin of 644.40% and a negative return on equity of 112.46%. The firm had revenue of $8.36 million during the quarter, compared to the consensus estimate of $3.68 million.

Institutional Trading of ASP Isotopes

Several hedge funds have recently made changes to their positions in ASPI. Encompass Capital Advisors LLC purchased a new stake in shares of ASP Isotopes in the first quarter valued at about $30,551,000. Alyeska Investment Group L.P. lifted its position in ASP Isotopes by 73.4% in the fourth quarter. Alyeska Investment Group L.P. now owns 4,895,546 shares of the company’s stock valued at $26,191,000 after purchasing an additional 2,072,851 shares during the period. UBS Group AG lifted its position in ASP Isotopes by 150.3% in the fourth quarter. UBS Group AG now owns 2,406,457 shares of the company’s stock valued at $12,875,000 after purchasing an additional 1,445,165 shares during the period. Marshall Wace LLP boosted its holdings in ASP Isotopes by 3,669.1% in the 3rd quarter. Marshall Wace LLP now owns 1,279,121 shares of the company’s stock valued at $12,305,000 after purchasing an additional 1,245,184 shares in the last quarter. Finally, Vanguard Group Inc. boosted its holdings in ASP Isotopes by 37.9% in the 3rd quarter. Vanguard Group Inc. now owns 4,516,763 shares of the company’s stock valued at $43,451,000 after purchasing an additional 1,241,024 shares in the last quarter. Institutional investors and hedge funds own 16.80% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ASP Isotopes in a report on Wednesday, June 24th. Canaccord Genuity Group reissued a “buy” rating and set a $11.00 price target on shares of ASP Isotopes in a report on Tuesday, April 14th. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, ASP Isotopes presently has a consensus rating of “Hold” and an average target price of $13.00.

ASP Isotopes Company Profile

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235. ASP Isotopes Inc was incorporated in 2021 and is headquartered in Washington, District Of Columbia.